AMTI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Molecular Transport Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.

Halper Sadeh encourages Applied Molecular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Applied Molecular and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Applied Molecular shareholders; (2) determine whether Cyclo is underpaying for Applied Molecular; and (3) disclose all material information necessary for Applied Molecular shareholders to adequately assess and value the merger consideration. On behalf of Applied Molecular shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Applied Molecular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.